Trial Profile
A Safety Study of Nivolumab in Patients With Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Pharyngeal neoplasms; Squamous cell cancer
- Focus Adverse reactions
- Acronyms TopNIVO; TOPNIVO (T)
- 24 Oct 2023 Results of patients with R/M SCCHN who progressed on nivolumab (N) and received SCT, presented at the 48th European Society for Medical Oncology Congress
- 17 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results of Patterns of radiological responses to anti-PD1, presented at the 47th European Society for Medical Oncology Congress